Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 21071055)

1.

Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.

Chen N, Bellone CJ, Schriewer J, Owens G, Fredrickson T, Parker S, Buller RM.

Virology. 2011 Jan 20;409(2):328-37. doi: 10.1016/j.virol.2010.10.021. Epub 2010 Nov 10.

2.

The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4.

Robbins SJ, Jackson RJ, Fenner F, Beaton S, Medveczky J, Ramshaw IA, Ramsay AJ.

Antiviral Res. 2005 Apr;66(1):1-7. Epub 2005 Jan 25.

PMID:
15781125
3.

A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.

Israely T, Paran N, Lustig S, Erez N, Politi B, Shafferman A, Melamed S.

Virol J. 2012 Jun 18;9:119. doi: 10.1186/1743-422X-9-119.

4.

Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.

Parker S, Chen NG, Foster S, Hartzler H, Hembrador E, Hruby D, Jordan R, Lanier R, Painter G, Painter W, Sagartz JE, Schriewer J, Mark Buller R.

Antiviral Res. 2012 Apr;94(1):44-53. doi: 10.1016/j.antiviral.2012.02.005. Epub 2012 Feb 18.

5.

Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

Parker S, Schriewer J, Oberle C, Robertson A, Lanier R, Painter G, Buller RM.

Antivir Ther. 2008;13(7):863-73.

6.
7.

A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants.

Alejo A, Saraiva M, Ruiz-Argüello MB, Viejo-Borbolla A, de Marco MF, Salguero FJ, Alcami A.

PLoS One. 2009;4(4):e5175. doi: 10.1371/journal.pone.0005175. Epub 2009 Apr 13.

8.

Ectromelia virus: the causative agent of mousepox.

Esteban DJ, Buller RM.

J Gen Virol. 2005 Oct;86(Pt 10):2645-59. Review.

9.

Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.

Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, Lampert B, Painter G, Buller RM.

Antiviral Res. 2008 Jan;77(1):39-49. Epub 2007 Sep 4.

PMID:
17904231
10.

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER.

Antimicrob Agents Chemother. 2007 Nov;51(11):4118-24. Epub 2007 Aug 27.

11.

Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.

Parker S, Siddiqui AM, Oberle C, Hembrador E, Lanier R, Painter G, Robertson A, Buller RM.

Virology. 2009 Mar 1;385(1):11-21. doi: 10.1016/j.virol.2008.11.015. Epub 2008 Dec 18.

12.

T cell cytokine synthesis at the single-cell level in BALB/c and C57BL/6 mice infected with ectromelia virus.

Szulc L, Gieryńska M, Winnicka A, Martyniszyn L, Boratyńska-Jasińska A, Niemiałtowski M.

Postepy Hig Med Dosw (Online). 2012 Apr 20;66:222-30.

13.

The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responses.

Melo-Silva CR, Tscharke DC, Lobigs M, Koskinen A, Wong YC, Buller RM, Müllbacher A, Regner M.

J Virol. 2011 Nov;85(21):11170-82. doi: 10.1128/JVI.00256-11. Epub 2011 Aug 17.

14.

Comparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T cells despite markedly different in vivo replication and pathogenicity.

Hersperger AR, Siciliano NA, Eisenlohr LC.

J Virol. 2012 Jul;86(13):7298-309. doi: 10.1128/JVI.00038-12. Epub 2012 Apr 24.

15.

Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.

Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY.

Virology. 2004 Jan 20;318(2):474-81.

PMID:
14972516
16.

Evaluating vaccinia virus cytokine co-expression in TLR GKO mice.

Sutherland DB, Ranasinghe C, Regner M, Phipps S, Matthaei KI, Day SL, Ramshaw IA.

Immunol Cell Biol. 2011 Aug;89(6):706-15. doi: 10.1038/icb.2010.157. Epub 2010 Dec 21.

PMID:
21173782
17.

Possible mechanism for the enhanced lethality of an interleukin-4-expressing mousepox virus.

Norazmi MN.

J Med Microbiol. 2001 Oct;50(10):936. No abstract available.

18.

A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.

Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, Parker S.

J Virol. 2010 Apr;84(8):3909-20. doi: 10.1128/JVI.02012-09. Epub 2010 Feb 3.

19.

Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox.

Chaudhri G, Panchanathan V, Buller RM, van den Eertwegh AJ, Claassen E, Zhou J, de Chazal R, Laman JD, Karupiah G.

Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9057-62. Epub 2004 Jun 7.

20.

Loss of cytoskeletal transport during egress critically attenuates ectromelia virus infection in vivo.

Lynn H, Horsington J, Ter LK, Han S, Chew YL, Diefenbach RJ, Way M, Chaudhri G, Karupiah G, Newsome TP.

J Virol. 2012 Jul;86(13):7427-43. doi: 10.1128/JVI.06636-11. Epub 2012 Apr 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk